• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Gyroscope Therapeutics to receive investment from Sanofi worth up to $60M

November 8, 2021 By Sean Whooley

Gyroscope TherapeuticsGyroscope Therapeutics announced today that it received a commitment from Sanofi (NYSE:SNY) to invest up to $60 million.

London-based Gyroscope will receive a $40 million investment from Sanofi initially. That $40 million represents a premium to Gyroscope’s previous Series C financing, with the remaining $20 million to be invested contingent on a future qualifying investment round and other certain closing conditions.

“We are thrilled to welcome Sanofi onboard as an investor in Gyroscope. Their investment is a testament to the promise of our science and gene therapy programs to make a difference for people with serious eye diseases,” Gyroscope CEO Khurem Farooq said in a news release. “We believe our lead investigational gene therapy, GT005, has the potential to be the first gene therapy for geographic atrophy, a devastating cause of vision loss for more than 5 million people globally, and were pleased to recently announce additional encouraging data from our ongoing Phase I/II FOCUS clinical trial.”

Under the agreement, a Sanofi R&D executive will join Gyroscope’s clinical advisory board to advise on matters related to the development of GT005. At the same time, the company also granted Sanofi an exclusive right of first refusal on certain potential future transactions for GT005 in select geographies.

Gyroscope said it plans to use proceeds from the investment to support funding of ongoing clinical trials for GT005, which has received fast track designation by the FDA and is currently under evaluation in Phase II clinical trials.

GT005 is an investigational gene therapy designed to treat geographic atrophy (GA) secondary to age-related macular degeneration (AMD. It represents part of the company’s early-stage pipeline that includes the proprietary Orbit subretinal delivery system that provides precise delivery of therapeutics to the back of the eye.

“Gyroscope’s ambition to develop gene therapies to treat geographic atrophy, a life-altering eye disease that has no approved treatments, aligns with our mission and our focus on pushing frontiers in genomic medicine,” Sanofi VP, Global Head of Genomic Medicine Christian Mueller said. “We are excited to be part of the Gyroscope story as they advance their promising investigational gene therapy, GT005, forward in clinical development.”

Filed Under: Business/Financial News, Clinical Trials, Drug-Device Combinations, Featured, Funding Roundup, Optical/Ophthalmic, Pharmaceuticals Tagged With: Gyroscope Therapeutics, sanofi

IN CASE YOU MISSED IT

  • Abbott could pave new roads in diabetes management with dual sensor on the horizon
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump
  • Beta Bionics to pair iLet automated insulin delivery system with Abbott’s dual glucose-ketone sensor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS